Children born small for gestational age (SGA) are
shorter that normal children during infancy, childhood and adolescence
and reach adult heights that on an average are approximately 1 SD lower
than the mean [1]. Therapy with growth hormone (GH) often augments
growth potential in short children born SGA [2].
The Food and Drug Administration (FDA) in 2001 and
the European Agency for the Evaluation of Medicinal Products in 2003
officially recommend GH therapy in children born SGA who fail to
catch-up. There are no Indian studies that describe the usefulness of GH
in short children born SGA.
We conducted this study to describe the growth
pattern of children born SGA from a pediatric endocrine clinic where
they presented with growth related complaints and to assess the efficacy
of GH in increasing height of children born SGA with growth failure.
Methods
This retrospective study is based on data retrieved
from case records of 81 SGA children who had been on regular follow-up
in a pediatric endocrine clinic for growth related complaints from
2005-2010. Details pertaining to anthropometry, clinical parameters and
investigations were collected from the case records. Children presenting
with growth related complaints had been assessed using a standard
protocol and anthropometric tools [3]. Children with birth weight
Z-score <-2 for their gestational age were included in the study.
Children with any major congenital malformations, syndromic features or
sequelae of intrauterine infections were excluded. All the study
subjects underwent GH stimulation tests to rule out GH deficiency.
These children were followed up every six months for
monitoring of growth. The anthropometric measures were converted into
Z-scores based on our earlier study on affluent children [4]. Pubertal
status was assessed by a pediatric endocrinologist [5]. Growth velocity
was converted into Z-score using references published by Tanner, et
al. [6] for pubertal children and Rikken, et al. [7] for
pre-pubertal children. Subjects were counselled for growth hormone
therapy if either the height for age Z-score <-2.5 or annual growth
velocity was below the mean for the corresponding age and sex or Height
SDS > 1 SD below midparental height SDS. Our hospital ethics committee
approved the study.
The subjects were divided into two groups:- Group I
children satisfied the auxological criteria and received growth hormone
in a dose of 35 µg/kg/day as a daily bedtime injection by the sub-cutaneous
route for a minimum period of two years. Group II children did not
receive growth hormone owing to logistic reasons.
Analysis of anthropometric and clinical parameters
were carried out using SPSS 16.0 (for windows), 2001. The changes in
anthropometry and growth velocity parameters of the two groups were
compared using the student t-test.
Results
We reviewed the case records of 81 children (mean age
7.6 ± 0.4 years, 30 boys) who satisfied the study criteria and were
followed up for a minimum period of two years. Finally we compared 20
SGA children who received GH and 20 age and sex matched children who did
not receive GH. Baseline characteristics of the two groups are compared
in Table I.
TABLE I Baseline Clinical and Anthropometric Characteristics
|
Group I (GH) |
Group II (Control)
|
|
(n=20) |
(n=20) |
Age ( y) |
7.7± 3.4 |
8.5 ± 3.4 |
Sex (M:F) |
7:13 |
7:13 |
Birthweight (kg) |
1.8 ± 0.3 |
1.8 ± 0.4 |
Gestational age (wks) |
39 ± 1 |
38.5 ±1 |
Target height (cm) |
156.7 ± 8.1 |
158.1 ± 8.7 |
Target height Z-score |
–1.07 ± 0.7 |
-0.9 ± 0.6 |
Height (cm) |
108.1±20.9 |
104.9 ± 25.4 |
Height for age Z-score |
–2.8 ± 1.3 |
–2.2 ± 1.7 |
Weight (kg) |
17.8 ± 8.8 |
20.05 ± 10.3 |
Weight for age Z-score |
–2.5 ± 1.5 |
–2.2 ± 1.9 |
Body Mass Index (kg/m2) |
14.3 ± 2.4 |
14.9 ± 4 |
Pubertal status |
11/20 |
12/20 |
All values are expressed as mean ± SD. Pubertal status
indicates testicular volume > 4 mL in boys or Tanner Breast
stage 2.
|
TABLE II Change in Anthropometric and Pubertal Status on Group I Children (Treated with GH)
Versus Controls in Group II
|
Group I (n=20) |
Group II (n=20) |
Growth velocity in the first year
(cm/year)* |
10.0 ± 2.1 |
5.8 ± 2.3 |
Growth velocity in the second year
(cm/year)* |
7.9 ± 1.6 |
5.5 ± 2.4 |
Growth velocity Z-score (1st year) * |
4.3 ± 0.5 |
0.5 ± 0.6 |
Growth velocity Z-score (2nd year)* |
1.7 ± 0.4 |
0.6 ± 0.7 |
|
Baseline |
Endline |
Baseline |
Endline |
Height (in cm)* |
108.1 ± 20.9 |
125.3 ± 18.8 |
104.9 ± 25.4 |
116.2 ± 19.7 |
Height for age Z-score* |
-2.8 ± 1.3 |
-1.6 ± 1.2 |
-2.2 ± 1.7 |
-1.7 ±1.1 |
Weight (in kg) |
17.8 ± 8.8 |
19.3 ± 7.6 |
20.05 ± 10.3 |
30.1 ± 15.7 |
Weight for age Z-score |
-2.5 ± 1.5 |
-2 ± 2.8
|
-2.2 ± 1.9 |
-1.6 ± 1.9 |
Body Mass Index (kg/m2) |
14.3 ± 2.4 |
13.2 ± 2.2 |
14.9 ± 4 |
19.3 ± 3.3 |
Pubertal status |
11/20 |
13/20 |
12/20 |
15/20 |
*P value <0.05. |
The results of the effect of GH on treated subjects
versus 20 controls are described in Table II. Growth
velocity of boys and girls from group I and II are depicted in
Web
Fig. 1 (a) and 1 (b), respectively, in comparison
with 50
centile. Growth Hormone therapy was not associated with any significant
adverse effects or acceleration of pubertal process.
Longitudinal studies on growth of SGA infants from
German [8], Belgium [9] and Spain [10] using country specific growth
charts demonstrate that SGA children have mean growth velocity Z-score
of -1.4, -1 and -2.1, respectively. The mean growth velocity in a study
on Argentanian children was 5.4 ± 1.7 cm [11]. The growth velocity
curves on cross sectional data of our children are in line with these
international studies.
There was a short term increase in height SDs in our
study group by + 1.2 from -2.8 to -1.6 after two years of GH therapy.
Our results are in line with previous reports [12-14]. There was no
acceleration of puberty in children treated with GH versus the
non-treated group in our study. This is in agreement with previous
reports that in the majority of short SGA children treated with GH
during childhood, pubertal development begins on time and progresses
normally [15]. However, longer follow-up is required to establish
whether all of our children will start puberty at an appropriate age and
whether the overall duration of puberty is altered.
Birth length has not been used to classify as SGA as
it could not be reliably retrieved from many records. Also, the
limitations in cross sectional data in assessing longitudinal growth are
well known. The effect on glucose metabolism in subjects treated with GH
could not be assessed. Also, our children need to be followed up till
they reach adult height to see if the catch-up is maintained and there
is an increase in the final attained height. Further, predicted height
could not be calculated as bone age is not a good predictor of final
height in SGA children. However, our results suggest that,
anthropometric parameters need to be monitored regularly in children
born SGA. GH is likely to be useful in augmentation of height and height
velocity in Indian children who are born SGA when they do not catch-up.
1. Karlberg J, Albertsson-Wikland K. Growth in full
term small-for-gestational-age infants: from birth to final height. Pediatr
Res. 1995;38:733-9.
2. Boguszewski MC, Mericq V, Bergada I, Damiani D, Belgorosky
A. Latin american consensus: children born small for gestational age.
BMC Pediatr. 2011; 11:66.
3. Wilma O, Floor K, Sabine M, Jan M. Diagnostic
approach in children with short stature. Horm Res. 2009;72:206-17.
4. Khadilkar VV, Khadilkar AV, Cole TJ, Sayyad MG.
Cross sectional growth curves for height, weight and body mass index for
affluent Indian children, 2007. Indian Pediatr. 2009;46:477-89.
5. Tanner JM. Growth and Adolescence, 2nd ed. Oxford,
England: Blackwell Scientific Publications, 1962.
6. Tanner JM, Whitehouse RH, Takaishi M. Standards
from birth to maturity for height, weight, height velocity, and weight
velocity: British Children, I965. Arch Dis Child. 1966;41:613.
7. Rikken B, Wit JM. Prepubertal height velocity
references over a wide age range. Arch Dis Child. 1992;67:1277-80.
8. Butenandt O, Lang G. Recombinant human growth
hormone in short children born small for gestational age. German study
group. J Pediatr Endocrinol Metab. 1997;10:275-82.
9. de Zegher F, Du Caju MV, Heinrichs C, Maes M, De
Schepper J. Early, discontinuous, high dose growth hormone treatment to
normalize height and weight of short children born small for gestational
age: results over 6 years. J Clin Endocrinol Metab. 1999;84:1558-61.
10. Argente J, Gracia R, Ibáńez L, Oliver A, Borrajo
E, Vela A, et al. Improvement in growth after two years of growth
hormone therapy in very young children born small for gestational age
and without spontaneous catch-up growth: Results of a multicenter,
controlled, randomized, open clinical trial. J Clin Endocrinol Metab. 2007;92:3095-101.
11. Bergadá I, Blanco M, Keselman DA, Domené y BHM,
Bergadá C. . Growth hormone treatment in younger than six years of age
short children born small for gestational age Arch Argent Pediatr.
2009;107:410-6.
12. de Zegher F, Wikland KA, Hartmut A, Chatelain P,
Chaussain J, Lofstrom A, et al. Growth hormone treatment of short
children born small for gestational age: Growth responses with
continuous and discontinuous regimens over 6 years. J Clin Endocrinol
Metab. 2000;85:2816-21.
13. Carel JC, Chatelain P, Rochiccioli P, Chaussain
J. Improvement in adult height after growth hormone treatment in
adolescents with short stature born small for gestational age: Results
of a randomized controlled study. J Clin Endocrinol Metab. 2003;88:
1587-93.
14. Boguszewski M, Bjarnason R, Rosberg S, Carlsson
LM, Albertsson-Wikland K. Growth hormone (GH)-binding protein in
prepubertal short children born small for gestational age: effects
of growth hormone treatment. Swedish Study Group for Growth
Hormone Treatment. J Clin Endocrinol Metab. 1997;82:1014-9.
15. Boonstra V, van Pareren Y, Mulder P,
Hokken-Koelega A. Puberty in growth hormone-treated children born small
for gestational age (SGA). J Clin Endocrinol Metab. 2003;88:5753-8.